Guggenheim Forecasts Strong Price Appreciation for Jade Biosciences (NASDAQ:JBIO) Stock

Jade Biosciences (NASDAQ:JBIO) had its target price lifted by equities researchers at Guggenheim from $17.00 to $23.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 58.84% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Wedbush reissued an “outperform” rating and issued a $24.00 price objective on shares of Jade Biosciences in a research note on Monday. Lifesci Capital raised Jade Biosciences to a “strong-buy” rating in a research report on Friday, March 6th. HC Wainwright began coverage on Jade Biosciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $25.00 price target on the stock. William Blair upgraded Jade Biosciences to a “strong-buy” rating in a research note on Monday. Finally, Wall Street Zen upgraded Jade Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $26.00.

Jade Biosciences Stock Performance

NASDAQ JBIO opened at $14.48 on Wednesday. Jade Biosciences has a one year low of $6.57 and a one year high of $100.10. The company has a market capitalization of $714.15 million, a price-to-earnings ratio of -3.14 and a beta of 1.03. The company’s 50-day simple moving average is $14.72 and its two-hundred day simple moving average is $12.05.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.34.

Institutional Trading of Jade Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. acquired a new position in Jade Biosciences during the 2nd quarter valued at about $17,703,000. Geode Capital Management LLC acquired a new stake in Jade Biosciences in the second quarter worth about $6,759,000. Versant Venture Management LLC acquired a new stake in Jade Biosciences in the second quarter worth about $15,243,000. Affinity Asset Advisors LLC purchased a new stake in shares of Jade Biosciences during the second quarter worth about $653,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Jade Biosciences during the second quarter valued at about $71,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.